Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 6/20 | 0.42 |
| ▸ | GAK | O14976 | 2/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.39 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608416 | 0.88 | ADRB2 (0.49) | GAKRIPK2COQ8ANLKADRB2 | |
| SCHEMBL21652114 | 0.86 | MAPK1 (0.37) | FGFR2GAKADRB2NCF1ALDH1A1 | |
| SCHEMBL17811239 | 0.85 | RIPK2 (0.48) | FGFR2GAKRIPK2COQ8ANLK | |
| SCHEMBL10315757 | 0.81 | HTR1A (0.51) | FGFR2ALDH1A1AAK1 | |
| SCHEMBL2608428 | 0.80 | NR4A2 (0.56) | ALOX15HSD17B10TDP1 | |
| SCHEMBL21325506 | 0.80 | ALOX5AP (0.42) | FGFR2GAKRIPK2COQ8ANLK | |
| SCHEMBL15043743 | 0.80 | FGFR2 (0.41) | FGFR2GAKRIPK2COQ8ANLK | |
| SCHEMBL11059904 | 0.80 | ALDH1A1 (0.47) | FGFR2GAKRIPK2COQ8ANLK | |
| SCHEMBL14549628 | 0.80 | FERMT2 (0.45) | GAKAAK1 | |
| SCHEMBL2608427 | 0.77 | HTR1A (0.55) | FGFR2GAKRIPK2COQ8ANLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210309679-A1 | BISPHOSPHONATE DRUG CONJUGATES | GUANGZHOU OTHROTX CO., LTD. (CN) | 2021-10-07 | — | — | US | disclosed |
| US-20200121806-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-9950076-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20160375147-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309679-A1 | BISPHOSPHONATE DRUG CONJUGATES | SOST, TGFB1, TGFB2 | FGFR2 78/4885GAK 2821/4885RIPK2 1726/4885 |
| US-20160375147-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | SLC10A1, HNMT, OGFR | FGFR2 2218/4885GAK 1870/4885RIPK2 4830/4885 |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | FGFR2 1989/4885GAK 1639/4885RIPK2 4825/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | FGFR2 26/4885GAK 1644/4885RIPK2 4106/4885 |
| US-20200121806-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | FGFR2 1989/4885GAK 1639/4885RIPK2 4825/4885 |
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | FGFR2 1989/4885GAK 1639/4885RIPK2 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.